Universität zu Köln

Journal Article

Al-Sawaf, Othman, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Herling, Carmen D., Hoechstetter, Manuela, Fink, Anna-Maria, von Tresckow, Julia, Langerbeins, Petra, Cramer, Paula, Stilgenbauer, Stephan, Wendtner, Clemens M., Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2018). Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br. J. Haematol., 183 (5). S. 727 - 736. HOBOKEN: WILEY. ISSN 1365-2141

Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). Am. J. Hematol., 94 (9). S. 1002 - 1007. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman, Lilienweiss, Esther, Bahlo, Jasmin, Robrecht, Sandra, Fink, Anna-Maria, Patz, Michaela, Tandon, Maneesh, Jiang, Yanwen, Schary, William, Ritgen, Matthias, Tausch, Eugen, Stilgenbauer, Stephan, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael and Kreuzer, Karl-Anton (2020). High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 135 (11). S. 866 - 871. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna Maria, Cramer, Paula, Maurer, Christian, Bergmann, Manuela A., Dreyling, Martin H., Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Dohner, Hartmut, Kiehl, Michael G., Jager, Ulrich, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara F. and Hopfinger, Georg (2016). Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Cramer, Paula, Maurer, Christian, Bergmann, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Jaeger, Ulrich, Wendtner, Clemens, Fischer, Kirsten, Goede, Valentin, Hallek, Michael, Eichhorst, Barbara, Hopfinger, Georg, Doehner, Hartmut and Kiehl, Michael (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis of the German CLL Study Group (GCLLSG). Leuk. Lymphoma, 58. S. 62 - 64. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Cramer, Paula, von Tresckow, Julia, Lange, Elisabeth, Kiehl, Michael, Dreyling, Martin, Rittgen, Matthias, Duerig, Jan, Fischer, Kirsten, Stilgenbauer, Stephan, Wendtner, Clemens, Goede, Valentin, Hallek, Michael and Eichhorst, Barbara (2020). Richter transformation in CLL: a meta-analysis of GCLLSG trials. Leuk. Lymphoma, 61. S. 98 - 101. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna Maria, Robrecht, Sandra, Tausch, Eugen, Schary, William L., Ritgen, Matthias, Wendtner, Clemens Martin, Kreuzer, Karl A., Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael J. and Fischer, Kirsten (2020). Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M., Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Du, Katell, Fogliatto, Laura M., Niemann, Carsten U., Weinkove, Robert, Robinson, Sue, Kipps, Thomas J., Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael and Fischer, Kirsten (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 21 (9). S. 1188 - 1201. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Beckmann, Laura, Berg, Valeska, Dickhut, Clarissa, Bloehdorn, Johannes, Bahlo, Jasmin, Robrecht, Sandra, Huelsemann, Malte, Loroch, Stefan, Merkel, Olaf, Fischer, Kirsten, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Sickmann, Albert ORCID: 0000-0002-2388-5265, Hallek, Michael, Zahedi, Rene and Frenzel, Lukas P. (2018). Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Beckmann, Laura ORCID: 0000-0001-5207-8991, Berg, Valeska, Dickhut, Clarissa, Sun, Clare ORCID: 0000-0001-8498-4729, Merkel, Olaf, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Robrecht, Sandra, Seifert, Marc, Guerreiro, Alexandra da Palma, Claasen, Julia, Loroch, Stefan, Oliverio, Matteo, Underbayev, Chingiz, Vaughn, Lauren, Thomalla, Daniel, Huelsemann, Malte F., Tausch, Eugen, Fischer, Kirsten, Fink, Anna Maria ORCID: 0000-0002-7669-7890, Eichhorst, Barbara, Sickmann, Albert ORCID: 0000-0002-2388-5265, Wendtner, Clemens M., Stilgenbauer, Stephan, Hallek, Michael, Wiestner, Adrian, Zahedi, Rene P. and Frenzel, Lukas P. (2021). MARCKS affects cell motility and response to BTK inhibitors in CLL. Blood, 138 (7). S. 544 - 557. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Braun, Andrejs ORCID: 0000-0003-0925-5598, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars ORCID: 0000-0002-5890-5510, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz ORCID: 0000-0002-3411-6357, Schneider, Christof, Gribben, John, Dahal, Lekh N., Carter, Mathew J., Elemento, Olivier, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J., Doehner, Hartmut, Stilgenbauer, Stephan and Mertens, Daniel (2021). Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nat. Commun., 12 (1). BERLIN: NATURE PORTFOLIO. ISSN 2041-1723

Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Krzykalla, Julia, Holzmann, Karlheinz, Gerhardinger, Andreas, Jebaraj, Billy Michael Chelliah, Bahlo, Jasmin, Humphrey, Kathryn, Tausch, Eugen, Robrecht, Sandra, Mertens, Daniel ORCID: 0000-0003-0227-7188, Schneider, Christof, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455, Doehner, Hartmut, Benner, Axel and Stilgenbauer, Stephan (2022). Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. Haematologica, 107 (3). S. 615 - 625. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Bloehdorn, Johannes, Krzykalla, Julia, Jebaraj, Billy Michael Chelliah, Holzmann, Karlheinz, Bahlo, Jasmin, Robrecht, Sandra, Humphrey, Kathryn, Wenger, Michael, Tausch, Eugen, Schneider, Christof, Bullinger, Lars, Fischer, Kirsten, Hallek, Michael, Mertens, Daniel, Benner, Axel, Doehner, Hartmut and Stilgenbauer, Stephan (2018). MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Brown, Jennifer, Tiao, Grace, Kasar, Siddha, Improgo, Ma Reina, Poh, Weijie, Kamburov, Atanas, Landau, Dan-Avi, Tausch, Eugen, Taylor-Weiner, Amaro, Cibulskis, Carrie, Bahl, Samira, Fernandes, Stacey, Hoang, Kevin, Kim, Haesook T., Bahlo, Jasmin, Rheinbay, Esther, Robrecht, Sandra, Fischer, Kirsten, Hallek, Michael, Gabriel, Stacey, Lander, Eric S., Stilgenbauer, Stephan, Wu, Catherine J., Kiezun, Adam and Getz, Gad (2017). Germline rare variant association analysis in chronic lymphocytic leukemia. Leuk. Lymphoma, 58. S. 126 - 128. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula ORCID: 0000-0003-4046-9922, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2022). Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial. Lancet Haematol., 9 (10). S. E745 - 11. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Cramer, Paula, Tausch, Eugen, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Furstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Pelzer, Benedikt W., Fink, Anna Maria ORCID: 0000-0002-7669-7890, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2021). Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood, 138 (19). S. 1805 - 1817. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Langerbeins, Petra, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Rittgen, Matthias, Kneba, Michael, Wendtner, Clemens, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2017). Sequential treatment with bendamustine, followed by obinutuzumab (GA101) and venetoclax (ABT-199) in patients with chronic lymphocytic leukemia (CLL): results of the CLL2-BAG phase-II-trial of the German CLL study group (GCLLSG). Leuk. Lymphoma, 58. S. 149 - 151. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Balke-Want, Hyatt, Al-Sawaf, Othman, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Fischer, Kirsten, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara F. and Hallek, Michael (2016). Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Al-Sawaf, Othman, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Tausch, Eugen, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2018). Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol., 19 (9). S. 1215 - 1229. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Fuerstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2018). Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz ORCID: 0000-0002-6593-0140, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO). Haematologica, 106 (2). S. 543 - 555. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Edelmann, Jennifer, Holzmann, Karlheinz, Tausch, Eugen, Saunderson, Emily A., Jebaraj, Billy M. C., Steinbrecher, Daniela, Dolnik, Anna, Blaette, Tamara J., Landau, Dan A., Saub, Jenny, Estenfelder, Sven, Ibach, Stefan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain ORCID: 0000-0002-1430-2574, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Goede, Valentin, Bullinger, Lars, Wu, Catherine J., Mertens, Daniel ORCID: 0000-0003-0227-7188, Ficz, Gabriella, Gribben, John G., Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2020). Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica, 105 (5). S. 1379 - 1391. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Estenfelder, Sven, Tausch, Eugen, Robrecht, Sandra, Bahlo, Jasmin, Goede, Valentin, Ritgen, Matthias, van Dongen, Jacques J. M., Langerak, Anton W., Fingerle-Rowson, Gunter, Kneba, Michael, Fischer, Kirsten, Hallek, Michael, Dohner, Hartmut and Stilgenbauer, Stephan (2016). Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fink, Anna Maria, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo ORCID: 0000-0003-3750-7342, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Dohner, Hartmut, Kneba, Michael, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2017). Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol., 4 (10). S. E475 - 12. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Fink, Anna-Maria, Robrecht, Sandra, Bahlo, Jasmin, Fuerstenau, Moritz, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Kater, Arnon, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Rittgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2020). Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy. Leuk. Lymphoma, 61. S. 272 - 274. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fuerstenau, Moritz, Fink, Anna Maria, Schilhabel, Anke, Weiss, Jonathan, Robrecht, Sandra, Eckert, Robert, de la Serna, Javier, Crespo, Marta ORCID: 0000-0002-7732-7808, Coscia, Marta, Vitale, Candida, Boettcher, Sebastian, Weppner, Gesche, Ritgen, Matthias, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara, Brueggemann, Monika and Herling, Carmen D. (2021). B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 137 (16). S. 2267 - 2272. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Giza, Adam, Stumpf, Thomas, Robrecht, Sandra, Maurer, Christian, Linde, Hartmut, Jacobasch, Lutz, Doerfel, Steffen, Aldaoud, Ali, von Tresckow, Julia, Koenigsmann, Michael, Gaska, Tobias, Kaiser, Ulrich, Harich, Hanns-Detlev, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Fink, Anna-Maria (2021). Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am. J. Hematol., 96 (12). S. E457 - 4. HOBOKEN: WILEY. ISSN 1096-8652

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Theurich, Sebastian (2018). Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, von Bergwelt-Baildon, Michael, Eichhorst, Barbara, Hallek, Michael and Theurich, Sebastian ORCID: 0000-0001-5706-8258 (2020). Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 34 (4). S. 1177 - 1182. LONDON: SPRINGERNATURE. ISSN 1476-5551

Fuerstenau, Moritz, Langerbeins, Petra, De Silva, Nisha, Fink, Anna Maria, Robrecht, Sandra, von Tresckow, Julia, Simon, Florian, Hohloch, Karin, Droogendijk, Jolanda, van der Klift, Marjolein, van der Spek, Ellen, Illmer, Thomas, Schoettker, Bjoern, Fischer, Kirsten, Wendtner, Clemens M., Tausch, Eugen, Stilgenbauer, Stephan, Niemann, Carsten U., Gregor, Michael, Kater, Arnon P., Hallek, Michael and Eichhorst, Barbara (2020). COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 34 (8). S. 2225 - 2230. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjorn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C., Lindstroem, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton and Kater, Arnon P. (2022). High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz ORCID: 0000-0002-6593-0140, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brueggemann, Monika, Eichhorst, Barbara, Hallek, Michael and Cramer, Paula ORCID: 0000-0003-4046-9922 (2022). Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clin. Cancer Res., 28 (19). S. 4203 - 4212. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Goede, Valentin, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Fink, Anna-Maria, Stilgenbauer, Stephan, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens (2017). Cumulative Illness Rating Scale (CIRS) provides prognostic information beyond the International Prognostic Index for chronic lymphocytic leukemia (CLL-IPI): analysis of 3 randomized trials of the German CLL Study Group. Leuk. Lymphoma, 58. S. 96 - 99. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Herling, Carmen D., Cymbalista, Florence, Gross-Ophoff-Mueller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael ORCID: 0000-0002-5277-4679, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Lepretre, Stephane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Doehner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Levy, Vincent (2020). Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia, 34 (8). S. 2038 - 2051. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Hoechstetter, Manuela A., Busch, Raymonde, Eichhorst, Barbara, Buhler, Andreas, Winkler, Dirk, Bahlo, Jasmin, Robrecht, Sandra, Eckart, Michael J., Vehling-Kaiser, Ursula, Jacobs, Georg, Jaeger, Ulrich, Hurtz, Hans Juergen, Hopfinger, Georg, Hartmann, Frank, Fuss, Harald, Abenhardt, Wolfgang, Blau, Ilona, Freier, Werner, Mueller, Lothar, Goebeler, Maria, Wendtner, Clemens, Fischer, Kirsten, Herling, Carmen D., Starck, Michael, Bentz, Martin, Emmerich, Bertold, Doehner, Hartmut, Stilgenbauer, Stephan and Hallek, Michael (2020). Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. Leukemia, 34 (4). S. 1038 - 1052. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Fuerstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael ORCID: 0000-0002-7425-4455, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 139 (9). S. 1318 - 1330. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Jaramillo, Sonia, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Doehner, Hartmut, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas and Stilgenbauer, Stephan (2020). Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group. Haematologica, 105 (11). S. 2598 - 2608. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Jebaraj, Billy Michael Chelliah, Tausch, Eugen, Landau, Dan A., Bahlo, Jasmin, Robrecht, Sandra, Taylor-Weiner, Amaro N., Bloehdorn, Johannes, Scheffold, Annika, Mertens, Daniel ORCID: 0000-0003-0227-7188, Boettcher, Sebastian, Kneba, Michael, Jaeger, Ulrich, Zenz, Thorsten, Wenger, Michael K., Fingerle-Rowson, Guenter, Wendtner, Clemens, Fink, Anna-Maria, Wu, Catherine J., Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2019). Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia, 33 (9). S. 2183 - 2195. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Julia, Von Tresckow, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Langerbeins, Petra, Fuerstenau, Moritz, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl A., Ritgen, Matthias, Boettcher, Sebastian, Wendtner, Clemens Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael J. (2018). Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Morita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas ORCID: 0000-0003-3864-8315, Thurner, Lorenz, Pfreundschuht, Michael, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus ORCID: 0000-0001-7080-4643, Hallek, Michael ORCID: 0000-0002-7425-4455, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz and Rixecker, Torben Millard (2022). KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematol., 9 (2). S. E133 - 10. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Kovacs, Gabor, Robrecht, Sandra, Fink, Anna Maria, Bahlo, Jasmin, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Langerbeins, Petra, Fingerle-Rowson, Gunter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Klapper, Wolfram, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Boettcher, Sebastian (2016). Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J. Clin. Oncol., 34 (31). S. 3758 - 3775. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Franklin, Jeremy, Zhang, Can, Maurer, Christian, De Silva, Nisha, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria, Hallek, Michael and Eichhorst, Barbara (2020). Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Hemasphere, 4 (1). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael, Soekler, Martin, Schlag, Rudolf, Fink, Anna-Maria, Vehling-Kaiser, Ursula, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Eichhorst, Barbara (2017). Health related quality of life (HRQOL) of patients treated with FCR vs BR within the CLL10 trial. Leuk. Lymphoma, 58. S. 109 - 111. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Fink, Anna Maria, Federhen, Anno, Giza, Adam, Robrecht, Sandra, Stumpf, Janina, Stoltefuss, Andrea, Vehling-Kaiser, Ursula, Koenigsmann, Michael, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Illmer, Thomas, Schlag, Rudolf, Doerfel, Steffen, Gaska, Tobias, Kiehl, Michael G., Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2022). Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry. Blood, 140. S. 9879 - 9882. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schueler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Mueller-Hagen, Sigrun, Heinisch, Karin, Boettcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens-Martin (2023). Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk. Lymphoma, 64 (2). S. 478 - 483. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trneny, Marek, Mulligan, Stephen P., Mey, Ulrich J. M., Trunzer, Kerstin, Fingerle-Rowson, Guenter, Humphrey, Kathryn, Stilgenbauer, Stephan, Boettcher, Sebastian, Brueggemann, Monika, Hallek, Michael, Kneba, Michael and van Dongen, Jacques J. M. (2019). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 133 (5). S. 494 - 498. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood, 139 (2). S. 177 - 188. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Mellinghoff, Sibylle C., Mayer, Leonie, Robrecht, Sandra, Weskamm, Leonie M., Dahlke, Christine ORCID: 0000-0002-2056-9195, Gruell, Henning, Schlotz, Maike, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Schloesser, Hans A., Thelen, Martin ORCID: 0000-0002-2785-9726, Fink, AnnaMaria, Fischer, Kirsten, Klein, Florian ORCID: 0000-0003-1376-1792, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael and Langerbeins, Petra (2022). SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia. Haematologica, 107 (10). S. 2480 - 2485. PAVIA: FERRATA STORTI FOUNDATION. ISSN 1592-8721

Mellinghoff, Sibylle C., Robrecht, Sandra, Mayer, Leonie ORCID: 0000-0001-7102-4358, Weskamm, Leonie M., Dahlke, Christine, Gruell, Henning, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Schloesser, Hans A., Thelen, Martin ORCID: 0000-0002-2785-9726, Fink, Anna-Maria, Fischer, Kirsten, Klein, Florian, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael and Langerbeins, Petra (2022). SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia, 36 (2). S. 562 - 566. LONDON: SPRINGERNATURE. ISSN 1476-5551

Pflug, Natali, Chakupurakal, Geothy, Fink, Anna-Maria, Robrecht, Sandra, Herling, Marco, Cramer, Paula, Holtick, Udo, Theurich, Sebastian ORCID: 0000-0001-5706-8258, Schetelig, Johannes, Fischer, Kirsten, Ritgen, Matthias, Scheid, Christof, Eichhorst, Barbara, Dreger, Peter, Hallek, Michael and von Bergwelt-Baildon, Michael (2021). Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. Hemasphere, 5 (12). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Pflug, Natali, Cramer, Paula, Robrecht, Sandra, Bahlo, Jasmin, Westermann, Anne, Fink, Anna-Maria, Schrader, Alexandra, Mayer, Petra, Oberbeck, Sebastian, Seiler, Till, Zenz, Thorsten, Duerig, Jan, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Herling, Marco and Hopfinger, Georg (2019). New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk. Lymphoma, 60 (3). S. 649 - 658. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Rusyn, Lisa, Reinartz, Sebastian, Nikiforov, Anastasia, Mikhael, Nelly, vom Stein, Alexander, Kohlhas, Viktoria, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Stilgenbauer, Stephan, Lohneis, Philipp, Buettner, Reinhard, Robrecht, Sandra, Fischer, Kirsten, Pallasch, Christian, Hallek, Michael ORCID: 0000-0002-7425-4455 and Seeger-Nukpezah, Tamina (2022). The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. Leukemia, 36 (7). S. 1794 - 1806. LONDON: SPRINGERNATURE. ISSN 1476-5551

Segura, Sonia Jaramillo, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Doehner, Hartmut, Brandell, Richard Rosenquist, Ghia, Paolo, Stamatopoulos, Kostas and Stilgenbauer, Stephan (2020). Prognostic impact of common chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Leuk. Lymphoma, 61. S. 135 - 137. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Simon, Florian, Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Fuerstenau, Moritz, Goede, Valentin, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455 and Al-Sawaf, Othman (2022). Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Leuk. Lymphoma, 63 (14). S. 3299 - 3307. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjoern, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Robrecht, Sandra, Zhang, Can, Dolnik, Anna, Bloehdorn, Johannes, Bahlo, Jasmin, Al-Sawaf, Othman, Ritgen, Matthias, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Tandon, Maneesh, Humphrey, Kathryn, Jiang, Yanwen, Schary, William, Bullinger, Lars, Mertens, Daniel, Lura, Michele Porro, Kneba, Michael, Doehner, Hartmut, Fischer, Kirsten, Hallek, Michael and Stilgenbauer, Stephan (2020). Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 135 (26). S. 2402 - 2413. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tiao, Grace, Improgo, M. Reina, Tausch, Eugen, Fernandes, Stacey M., Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Kiezun, Adam, Getz, Gad and Brown, Jennifer R. (2017). Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood, 130 (22). S. 2443 - 2445. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Wolf, Christine, Garding, Angela, Filarsky, Katharina, Bahlo, Jasmin, Robrecht, Sandra, Becker, Natalia, Zucknick, Manuela ORCID: 0000-0003-1317-7422, Rouhi, Arefeh, Weigel, Anja, Claus, Rainer ORCID: 0000-0003-2617-8766, Weichenhan, Dieter, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Kuchenbauer, Florian, Plass, Christoph, Doehner, Hartmut, Stilgenbauer, Stephan, Lichter, Peter and Mertens, Daniel ORCID: 0000-0003-0227-7188 (2018). NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int. J. Cancer, 142 (2). S. 322 - 334. HOBOKEN: WILEY. ISSN 1097-0215

Yosifov, Deyan Yordanov ORCID: 0000-0002-5473-4398, Idler, Irina, Bhattacharya, Nupur, Reichenzeller, Michaela, Close, Viola, Ezerina, Daria ORCID: 0000-0002-3104-7093, Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Kugler, Sabrina, Bloehdorn, Johannes, Bahlo, Jasmin, Robrecht, Sandra, Eichhorst, Barbara, Fischer, Kirsten, Weigel, Anja, Busch, Hauke ORCID: 0000-0003-4763-4521, Lichter, Peter, Doehner, Hartmut, Dick, Tobias P., Stilgenbauer, Stephan and Mertens, Daniel ORCID: 0000-0003-0227-7188 (2020). Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia, 34 (1). S. 115 - 128. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Bottcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael (2019). CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 33 (5). S. 1161 - 1173. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

von Tresckow, Julia ORCID: 0000-0001-5873-4603, Cramer, Paula ORCID: 0000-0003-4046-9922, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Fuerstenau, Moritz, Illmer, Thomas, Klaproth, Holger, Tausch, Eugen, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael ORCID: 0000-0002-7425-4455 (2022). Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia, 36 (8). S. 2125 - 2129. LONDON: SPRINGERNATURE. ISSN 1476-5551